A Muruganathan
Impact in
-
- Antibiotic Use and Resistance
- Molecular Medicine top 10%
- Antibiotic Resistance in Bacteria
Papers in
-
- Diabetes Management and Research 7
- Hyperglycemia and glycemic control in critically ill and hospitalized patients 3
- Diabetes, Cardiovascular Risks, and Lipoproteins 3
-
- Liver Disease Diagnosis and Treatment 3
- Pneumonia and Respiratory Infections 2
- Co-authors
- Malaisamy Muniyandi (1 shared paper)Aleyamma Thomas (1 shared paper)Rajesh Kumar Upadhyay (2 shared papers)Ashok Kumar Das (8 shared papers)Shivaram Prasad Singh (1 shared paper)Banshi Saboo (4 shared papers)Vivek A. Saraswat (1 shared paper)Radha K. Dhiman (1 shared paper)
- Journals
- Journal of the American College of Cardiology (1 paper)Journal of Clinical Hypertension (1 paper)Journal of the Association of Physicians of India (6 papers)Journal of Clinical and Experimental Hepatology (1 paper)International Journal of Diabetes in Developing Countries (1 paper)
- Partner nations
- IndiaUnited StatesAustralia
In The Last Decade
A Muruganathan
29 papers receiving 473 citations
Peers
Comparison fields: 5 of 78
- Applied Microbiology and Biotechnology 72
- Molecular Medicine 54
- Endocrinology, Diabetes and Metabolism 94
- Hepatology 33
- Epidemiology 136
Countries citing papers authored by A Muruganathan
This map shows the geographic impact of A Muruganathan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Muruganathan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Muruganathan more than expected).
Fields of papers citing papers by A Muruganathan
This network shows the impact of papers produced by A Muruganathan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Muruganathan. The network helps show where A Muruganathan may publish in the future.
Co-authors
The 25 scholars most cited alongside A Muruganathan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 130 | |
| 2 | 2013 | 89 | |
| 3 | Lipid Association of India Expert Consensus Statement on Management of Dyslipidemia in Indians 2016: Part 1. | 2016 | 49 |
| 4 | Revised National Tuberculosis Control Programme (RNTCP). | 2010 | 45 |
| 5 | 2018 | 30 | |
| 6 | API Recommendations for the Management of Typhoid Fever. | 2015 | 22 |
| 7 | Consensus evidence-based guidelines for management of gestational diabetes mellitus in India. | 2014 | 19 |
| 8 | "The Chennai Declaration" Recommendations of "A roadmap- to tackle the challenge of antimicrobial resistance" - A joint meeting of medical societies of India | 2012 | 17 |
| 9 | The Impact of Cultural Dimensions of Clinicians on the Adoption of Artificial Intelligence in Healthcare. | 2022 | 12 |
| 10 | 2016 | 9 | |
| 11 | Consensus recommendations for the management of hyperglycaemia in critically ill patients in the Indian setting. | 2014 | 9 |
| 12 | Indian National Consensus Group: NationalGuidelines on Initiation and Intensification of Insulin Therapy with Premixed Insulin Analogs | 2013 | 9 |
| 13 | Wilson's Disease with Systemic Lupus Erythematosus. | 2016 | 9 |
| 14 | Consensus evidence-based guidelines for insulin initiation, optimization and continuation in type 2 diabetes mellitus. | 2014 | 8 |
| 15 | Consensus evidence-based guidelines for in-patient management of hyperglycaemia in non-critical care setting as per Indian clinical practice. | 2014 | 7 |
| 16 | Indian College of Physicians (ICP) Position Statement on Pharmacovigilance. | 2017 | 4 |
| 17 | Prevalence of Hypertension among Urban Poor with and without Diabetes - A Study from South India. | 2019 | 3 |
| 18 | 2020 | 3 | |
| 19 | Consensus evidence-based guidelines for use of insulin pump therapy in the management of diabetes as per Indian clinical practice. | 2014 | 3 |
| 20 | Lipemia Retinalis due to Secondary Hyperlipidemia in Type 1 Diabetes Mellitus. | 2016 | 3 |
About A Muruganathan
A Muruganathan is a scholar working on Endocrinology, Diabetes and Metabolism, Epidemiology, Cardiology and Cardiovascular Medicine, Infectious Diseases and Pathology and Forensic Medicine, having authored 33 papers that have together received 491 indexed citations. Recurring topics across this work include Diabetes Management and Research (7 papers), Hyperglycemia and glycemic control in critically ill and hospitalized patients (3 papers), Diabetes and associated disorders (3 papers), Liver Disease Diagnosis and Treatment (3 papers), Blood Pressure and Hypertension Studies (3 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (3 papers), Drug-Induced Hepatotoxicity and Protection (2 papers) and Pneumonia and Respiratory Infections (2 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (72 citations), Molecular Medicine (54 citations), Endocrinology, Diabetes and Metabolism (94 citations), Hepatology (33 citations) and Epidemiology (136 citations). A Muruganathan has collaborated with scholars based in India, United States and Australia. Frequent co-authors include Malaisamy Muniyandi, Aleyamma Thomas, Rajesh Kumar Upadhyay, Ashok Kumar Das, Shivaram Prasad Singh, Banshi Saboo, Vivek A. Saraswat, Radha K. Dhiman, Yogesh Chawla and Ajay Duseja. Their work appears in journals such as Journal of the American College of Cardiology, Journal of Clinical Hypertension, Journal of the Association of Physicians of India, Journal of Clinical and Experimental Hepatology and International Journal of Diabetes in Developing Countries.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.